Navigation Links
American Stock Exchange Accepts Encision's Plan to Regain Compliance
Date:10/4/2007

BOULDER, Colo., Oct. 4 /PRNewswire-FirstCall/ -- On October 3, 2007, Encision Inc. (Amex: ECI) ("Encision" or the "Company") received a letter from the American Stock Exchange ("AMEX") stating that AMEX has accepted the Company's plan to regain compliance with AMEX's continued listing standards, and granted the Company an extension until January 16, 2009 to regain compliance with the continued listing standards.

As previously disclosed, on July 16, 2007, the Company received a letter from AMEX stating that the Company was not in compliance with Section 1003(a)(ii) of the Amex Company Guide due to stockholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three out of four of its most recent fiscal years. On August 15, 2007, the Company provided AMEX with information regarding its plan of compliance and financial projections. Based on a review of this information and conversations between AMEX Staff and the Company's representatives, AMEX has agreed to extend the period by which the Company must regain compliance with its listing standards until January 16, 2009.

The Company will be subject to periodic review by the AMEX Staff regarding its compliance plan during the extension period. Failure to make progress consistent with the plan could result in commencement of immediate delisting proceedings by AMEX.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward- looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie

Encision Inc.

303-444-2600

mmchaffie@encision.com


'/>"/>
SOURCE Encision Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Abstain from sex- the latest mantra of American teens
2. Clintons new problem - Is the outgoing American president suffering from skin cancer?
3. American scientists alter gene makeup of babies
4. FDA attacks American Red Cross for blood violations
5. Poll Finds Many Americans Misinformed About Cancer
6. Poll Finds Many Americans Misinformed About Cancer
7. Hypertension Drug of Choice for African Americans
8. 38 million Americans including 14 million children left to combat hunger
9. Americans Consume Far Too Much Salt and Sodium
10. Americans Growing Out Of Shape
11. Rise in Stress among Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New Jersey ... as well as advocacy for the state and region‘s technology businesses, hosted their ... The Council's Innovation Forecast event highlights innovation throughout the region from small to ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology: